B

    Bicycle Therapeutics Ltd (BCYC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.20
    -0.13 (-3.00%)

    Market Cap: $293.97M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    41%(12/29)
    Avg Surprise
    -7.53%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.46
    Range$-0.65 - $-0.04
    8 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.50-8.8%
    60d ago$-0.49-7.5%
    30d ago$-0.49-7.5%
    7d ago$-0.50-9.3%
    Current$-0.46
    Revenue Consensus
    $12M
    Range$598000 - $34M
    9 analysts
    Dec 31, 2026
    EPS Consensus$-0.78
    Range$-1.13 - $0.33
    8 analysts
    Revenue Consensus
    $-6132800
    Range$-21000000 - $14M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.78---
    Sep 26EST
    		-$-0.46---
    Jun 26
    		$-0.72$-0.37-94.59%Miss+36.8%
    Mar 26
    		$-0.87$-0.67-29.85%Miss+1.1%
    Dec 25
    		$-0.29N/A+69.06%Beat+64.4%
    Sep 25
    		$-0.85$-1.07+20.56%Beat-18.1%
    Jun 25
    		$-1.14$-0.93-22.58%Miss-48.1%
    Mar 25
    		$-0.88$-0.85-3.53%Miss-41.9%
    Dec 24
    		$-0.81$-0.85+4.59%Beat+29.8%
    Sep 24
    		$-0.72$-0.78+7.69%Beat+42.9%
    Jun 24
    		$-0.77$-1.11+30.63%Beat+45.4%
    Mar 24
    		$-0.62$-1.21+48.76%Beat+52.3%
    Dec 23
    		$-1.16$-1.23+5.69%Beat-14.9%
    Sep 23
    		$-1.26$-1.06-18.87%Miss-31.3%
    Jun 23
    		$-1.41$-1.07-31.78%Miss-56.7%
    Mar 23
    		$-1.30$-0.96-35.42%Miss-39.8%
    Dec 22
    		$-1.01$-1.06+4.72%Beat-60.3%
    Sep 22
    		$-0.96$-0.91-5.49%Miss-62.7%
    Jun 22
    		$-0.90$-0.81-11.11%Miss-21.6%
    Mar 22
    		$-0.93$-0.72-29.17%Miss-27.4%
    Dec 21
    		$-0.63$-0.61-3.28%Miss+24.1%
    Sep 21
    		$-0.59$-0.63+6.35%Beat-13.5%
    Jun 21
    		$-0.74$-0.67-10.45%Miss-10.4%
    Mar 21
    		$-0.73$-0.71-2.82%Miss-15.9%
    Dec 20
    		$-0.83$-0.47-76.60%Miss-232.0%
    Sep 20
    		$-0.52$-0.53+1.89%Beat+1.9%
    Jun 20
    		$-0.67$-0.46-45.65%Miss-1.5%
    Mar 20
    		$-0.63$-0.38-65.79%Miss-40.0%
    Dec 19
    		$-0.25N/A+51.92%Beat+67.9%
    Sep 19
    		$-0.53$-0.69+23.19%Beat-41.5%
    Jun 19
    		$-0.66$-0.62-6.45%Miss-246.3%
    Mar 19
    		$-0.45N/AN/ABeat-19.7%
    Sep 18
    		$-0.78$0.00N/AMiss-
    Jun 18
    		$-0.37N/AN/ABeat-
    Mar 18
    		$-0.19N/AN/ABeat-
    Dec 17
    		$-0.38N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.54EV/EBITDA-2.14x
    Price/FCF-1.40xFCF Yield-71.34%
    Profitability
    Profit Margin0.00%Operating Margin-8674.00%
    ROE-32.30%ROIC-35.98%
    Financial Health
    Debt/Equity0.03xInterest Coverage-976.62x
    Current Ratio12.08xQuick Ratio12.08x
    Trading Statistics
    Beta1.53Avg Volume290.14K
    52-Week High$9.1652-Week Low$3.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.23
    SMA 20$4.12
    SMA 50$4.13
    SMA 200$5.25
    EMA 10$4.24
    EMA 20$4.18
    EMA 50$4.20
    EMA 200$5.22

    MACD

    Line: 0.06Signal: 0.03Hist: 0.03

    ADX

    ADX: 23.3+DI: 26.6-DI: 15.2

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down24.0
    PSAR$4.00

    Bollinger Bands

    Upper Band$4.46
    Lower Band$3.78
    %B Position1644%(Upper)
    Band Width0.62

    RSI (14-Day)

    Neutral
    51.9

    Momentum Oscillators

    Stoch %K66.4
    Stoch %D73.0
    Williams %R-48.4
    ROC (10d)7.7%
    Momentum0.30
    CCI (20d)71.4
    MFI (14d)48.6

    Volatility Measures

    ATR (14d)$0.16(3.9%)
    StdDev (20d)0.17
    Hist Vol33.8%(Moderate)

    Volume Flow

    VWAP$4.28
    OBV1.7M
    AD Line-18.0M
    CMF (20d)-0.027

    Volume Metrics

    Avg Vol (20d)281.4K
    Vol Ratio0.5x
    VWMA (20d)$4.10

    Pivot Points

    R3$4.60
    R2$4.52
    R1$4.43
    Pivot Point$4.35
    S1$4.26
    S2$4.18
    S3$4.09

    Advanced Oscillators

    TSI10.97
    Ultimate Osc45.7
    KST28.73

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$629,000$887,000$47.95M$11.73M$2.92M$9.98M$3.71M$2.68M$9.36M$19.53M$5.33M$5.35M
    Cost of RevenueN/AN/A$35.06MN/A$71.03M$57.27M$56.07M$45.65M$1.64M$1.66M$1.67M$151.61M
    Gross Profit$629,000$887,000$47.95M$11.73M$-68,109,000$-47,294,000$-52,364,000$-42,972,000$9.36M$19.53M$5.33M$5.35M
    Operating Expenses$55.19M$66.48M$72.61M$77.28M$18.49M$22.91M$15.30M$20.87M$56.01M$51.25M$59.57M$56.15M
    R&D$41.16M$48.90M$51.77M$58.43M$71.03M$59.06M$49.78M$48.27M$40.06M$34.86M$44.70M$39.87M
    SG&A$14.03M$17.57M$20.84M$19.02M$19.24M$21.12M$21.02M$18.26M$16.05M$16.45M$15.05M$15.57M
    Operating Income$-54,559,000$-65,589,000$-24,657,000$-65,551,000$-86,602,000$-70,204,000$-67,663,000$-63,846,000$-46,647,000$-31,716,000$-54,235,000$-50,797,000
    Interest Income$4.36M$4.88M$5.88M$6.70M$7.47M$8.41M$10.30M$10.58M$7.77M$5.62M$6.28M$3.98M
    Interest Expense$44,000$48,000$57,000$44,000$54,000$51,000$52,000$33,000$824,000$821,000$820,000$814,000
    Income Before Tax$-50,243,000$-60,653,000$-18,889,000$-58,895,000$-79,183,000$-61,841,000$-52,951,168$-54,250,000$-39,697,000$-26,913,000$-48,779,000$-47,626,000
    Income Tax Expense$90,000$172,000$1.26M$205,000$-231,000$-1,087,000$-1,082,000$-3,448,000$115,000$-350,000$320,000$2.27M
    Net Income$-50,333,000$-60,825,000$-20,154,000$-59,100,000$-78,952,000$-60,754,000$-51,854,000$-50,802,000$-39,812,000$-26,563,000$-49,099,000$-49,898,000
    EBITDA$-49,132,000$-59,476,000$-17,496,000$-57,095,000$-77,433,000$-60,251,727$-51,195,168$-61,208,384$-37,233,000$-24,434,000$-46,305,000$-45,122,000
    EBIT$-50,199,000$-60,605,000$-18,832,000$-58,851,000$-79,129,000$-61,892,000$-52,899,168$-63,402,660$-38,873,000$-26,092,000$-47,959,000$-46,812,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BCYC

    News

    Possible Signal As Bicycle Therapeutics Insiders Sell US$523k In Stock

    Bicycle Therapeutics (NASDAQ:BCYC) insiders have sold US$523k worth of stock over the past year, primarily at an average price higher than the current market price. While the company's stock jumped 12% last week, the recent insider selling, especially a US$141k sale by the CEO, suggests potential caution. Despite a 1.3% insider ownership, which is considered low, no insider purchases have occurred in the last year, prompting a wary stance for potential investors.

    Simply Wall Street•8/22/26•
    Somewhat-Bearish

    Armistice Capital (BCYC) reports 3.40M Bicycle Therapeutics ADSs in 13G/A

    Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 3,398,000 American Depositary Shares (ADSs) of Bicycle Therapeutics plc (BCYC). This represents 6.72% of the outstanding class as of June 30, 2026. All voting and dispositive power over these shares is shared between Armistice Capital, as investment manager, and Mr. Boyd, as its managing member.

    Stock Titan•8/14/26•
    Neutral

    Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Hold" by Analysts

    Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has received a consensus "Hold" rating from nine analysts, with an average 12-month price target of $13.86, significantly higher than its current $4.17. The company recently missed earnings and revenue expectations, reporting a loss of $0.72 per share against an anticipated $0.58 loss, and $0.63 million in revenue compared to a $4.22 million estimate. Despite a recent 5% stock increase, BCYC remains near its 52-week low, with institutional investors holding a large stake and insiders primarily selling shares to cover tax obligations.

    MarketBeat•8/8/26•
    Somewhat-Bearish

    Renaissance Technologies LLC Buys 412,700 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC

    Renaissance Technologies LLC significantly increased its stake in Bicycle Therapeutics PLC (NASDAQ:BCYC) by 72.8%, acquiring an additional 412,700 shares to own a total of 979,300 shares, representing approximately 1.4% of the company. This move comes amidst mixed analyst ratings and Bicycle Therapeutics reporting a larger-than-expected quarterly loss and lower-than-anticipated revenue. Despite insider selling by the CEO, institutional investors collectively own a substantial portion of the stock.

    MarketBeat•8/7/26•
    Neutral

    BCYC|Bicycle Therapeutics PLC|Price:3.875|Chg%:+0.015

    Bicycle Therapeutics PLC (BCYC) shows strong fundamentals and significant growth potential, despite recent weak market performance. TradingKey's analysis rates its valuation as fairly valued, with high institutional ownership. Analysts have given the stock a "Buy" rating, setting a high price target, though the stock is expected to trend down in the medium term.

    TradingKey•8/4/26•
    Somewhat-Bullish

    Frequently Asked Questions About BCYC

    Does BCYC pay dividends?
    Bicycle Therapeutics Ltd (BCYC) does not currently pay a regular dividend.
    What is BCYC's market cap?
    Bicycle Therapeutics Ltd (BCYC) has a market capitalization of $293.97M with a current stock price of $4.20.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In